Celanese Presents Cutting-edge Pharmaceutical Copolymer at 2016 AAPS Annual Meeting and Expo

SHARE


Poster presentation demonstrates advantages of EVA in controlled
release drug delivery

DALLAS & DENVER–(BUSINESS WIRE)–
Celanese Corporation (NYSE: CE), a global technology and specialty
materials company, will present its EVA pharmaceutical material
solutions at the 2016
AAPS Annual Meeting and Exposition
November 13-17 at the Colorado
Convention Center in Denver. Celanese will exhibit its pharmaceutical
controlled release copolymer, VitalDose® ethylene vinyl acetate (EVA),
at booth 1604.

Celanese material experts will discuss the latest developments in
pharmaceutical material science and how EVA is being used in new drug
delivery innovations. VitalDose® EVA controlled release excipients
deliver reliable performance with customizable release properties that
are compatible with many active pharmaceutical ingredients (APIs).

When formulating thermally sensitive APIs with excipients in the hot
melt extrusion process, one of the major challenges is to make sure the
APIs do not go through any thermal degradation. This will not only
provide cost savings but also ensure the chemical integrity of the APIs
during processing. Due to their intrinsic low melting points, broad
melting ranges, and sheer thinning characteristics, EVA excipients
provide outstanding low temperature processability along with their
excellent controlled release properties and biocompatibility.

To help formulation scientists understand the processability temperature
ranges of EVA excipients, Celanese has conducted experiments to show the
minimum compounding temperatures of EVA excipients with vinyl acetate
contents ranging from 9% to 40%. At AAPS, Celanese will demonstrate
experiments of a tunable controlled release of Niacin with EVA
excipients prepared by a low temperature hot melt extrusion process. The
information provided with this original research will help formulation
scientists better address the challenges in formulating thermally
sensitive drugs by using EVA excipients.

Celanese will be presenting a poster session at the 2016 AAPS Annual
Meeting and Exposition highlighting EVA’s processing advantages for drug
formulators.

Celanese Poster Presentation:

Presenter:       Dirk Hair, Technology & Innovation Manager – Product Development
Title: Ethylene Vinyl Acetate Copolymer Excipients: Low Temperatures
Extrusion Processability and Controlled Release
Date: Tuesday, November 15, 2016
Poster#: 19T0100
 

“The unique properties of EVA controlled release excipients allow for
customizable delivery rates that are expanding pharmaceutical
possibilities,” said Susan Rahe, global business director of the
Celanese EVA polymers business. “VitalDose® EVA offers flexible delivery
systems and process versatility backed by high-touch technical expertise
to assist from project conception through design and regulatory
approval.”

For more information about Celanese’s controlled release pharmaceutical
EVA polymer, VitalDose® EVA, please visit http://healthcare.celanese.com/.

About Celanese

Celanese Corporation is a global technology leader in the production
of differentiated chemistry solutions and specialty materials used in
most major industries and consumer applications. Our two complementary
business cores, Acetyl Chain and Materials Solutions, use the full
breadth of Celanese’s global chemistry, technology and business
expertise to create value for our customers and the corporation. As we
partner with our customers to solve their most critical business needs,
we strive to make a positive impact on our communities and the world
through The Celanese Foundation. Based in Dallas, Celanese employs
approximately 7,000 employees worldwide and had 2015 net sales of $5.7
billion. For more information about Celanese and our product offerings,
visit
www.celanese.com
or our blog at
www.celaneseblog.com.

All registered trademarks are owned by Celanese International
Corporation or its affiliates.

Forward-Looking Statements

This release may contain “forward-looking statements,” which include
information concerning the company’s plans, objectives, goals,
strategies, future revenues or performance, capital expenditures,
financing needs and other information that is not historical
information. When used in this release, the words “outlook,” “forecast,”
“estimates,” “expects,” “anticipates,” “projects,” “plans,” “intends,”
“believes,” and variations of such words or similar expressions are
intended to identify forward-looking statements. All forward-looking
statements are based upon current expectations and beliefs and various
assumptions. There can be no assurance that the company or its customers
will realize these benefits or that these expectations will prove
correct. There are a number of risks and uncertainties that could cause
actual results to differ materially from the forward-looking statements
contained in this release. Numerous factors, many of which are beyond
the company’s control, could cause actual results to differ materially
from those expressed as forward-looking statements. Other risk factors
include those that are discussed in the company’s filings with the
Securities and Exchange Commission. Any forward-looking statement speaks
only as of the date on which it is made, and the company undertakes no
obligation to update any forward-looking statements to reflect events or
circumstances after the date on which it is made or to reflect the
occurrence of anticipated or unanticipated events or circumstances.

Celanese Corporation
Investor Relations
Chuck Kyrish,
+1-972-443-4574
chuck.kyrish@celanese.com
or
Media
Relations – Global

W. Travis Jacobsen, +1-972-443-3750
william.jacobsen@celanese.com
or
Media
Relations Asia (Shanghai)

Helen Zhang, +86 21 3861 9279
lan.zhang@celanese.com
or
Media
Relations Europe (Germany)

Jens Kurth, +49(0)69 45009 1574
j.kurth@celanese.com

Source: Celanese Corporation